Literature DB >> 9047385

Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells.

N Beauchemin1, T Kunath, J Robitaille, B Chow, C Turbide, E Daniels, A Veillette.   

Abstract

Biliary glycoprotein (Bgp) is a member of the immunoglobulin superfamily and the carcinoembryonic antigen family. Previous studies have shown that Bgp functions as an intercellular adhesion molecule and a canalicular bile salt transporter. Moreover, we and others demonstrated that Bgp can inhibit colonic and prostatic tumor cell growth in vivo, through a mechanism which depends on sequences present in its cytoplasmic domain. In this study, we have examined the possibility that the cytoplasmic domain of Bgp can interact with signal transduction molecules. We showed that tyrosine phosphorylated Bgp, expressed in mouse colon carcinoma CT51 cells, could reversibly associate with protein tyrosine phosphatase SHP-1. Mutation of either of two tyrosine residues present in the cytoplasmic domain of Bgp abrogated SHP-1 binding, suggesting that this association was mediated by both tyrosine residues. Similarly, we noted that either of the two SH2 domains of SHP-1 could bind tyrosine phosphorylated Bgp in vitro. It is therefore conceivable that some of the functions of Bgp are mediated through its ability to induce intracellular protein tyrosine dephosphorylation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9047385     DOI: 10.1038/sj.onc.1200888

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  Tyrosine phosphatase SHP-1 is involved in CD66-mediated phagocytosis of Opa52-expressing Neisseria gonorrhoeae.

Authors:  C R Hauck; E Gulbins; F Lang; T F Meyer
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

Review 2.  Negative signaling in health and disease.

Authors:  K M Coggeshall
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

3.  The CEACAM1-L glycoprotein associates with the actin cytoskeleton and localizes to cell-cell contact through activation of Rho-like GTPases.

Authors:  S Sadekova; N Lamarche-Vane; X Li; N Beauchemin
Journal:  Mol Biol Cell       Date:  2000-01       Impact factor: 4.138

4.  Sequential activation of ERK and repression of JNK by scatter factor/hepatocyte growth factor in madin-darby canine kidney epithelial cells.

Authors:  R Paumelle; D Tulasne; C Leroy; J Coll; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  2000-11       Impact factor: 4.138

5.  Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells.

Authors:  Azadeh Arabzadeh; Jeremy Dupaul-Chicoine; Valérie Breton; Sina Haftchenary; Sara Yumeen; Claire Turbide; Maya Saleh; Kevin McGregor; Celia M T Greenwood; Uri David Akavia; Richard S Blumberg; Patrick T Gunning; Nicole Beauchemin
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

6.  Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner.

Authors:  Elizabeth O Lobo; Zhifang Zhang; John E Shively
Journal:  J Leukoc Biol       Date:  2009-05-19       Impact factor: 4.962

7.  Switched at birth: a new family for PECAM-1.

Authors:  P J Newman
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

Review 8.  SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.

Authors:  Ulrike Lorenz
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  Generation of human CEACAM1 transgenic mice and binding of Neisseria Opa protein to their neutrophils.

Authors:  Angel Gu; Zhifang Zhang; Nan Zhang; Walter Tsark; John E Shively
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

Review 10.  Harnessing the platelet signaling network to produce an optimal hemostatic response.

Authors:  Lawrence F Brass; Maurizio Tomaiuolo; Timothy J Stalker
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-11       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.